MEDFORD, MASSACHUSETTS – October 26, 2021 – Travera announced today that it has received certification from the U.S. Department of Health and Human Services’ Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 for its cancer biomarker testing laboratory in Medford, Massachusetts. The CLIA regulations include federal standards applicable to all U.S. facilities or sites that test human specimens for health assessment or to diagnose, prevent, or treat disease. CMS regulates this testing in the United States through the CLIA.
“With the recent move to our expanded facility in Medford and this initial CLIA certification, we have achieved two key milestones which will enable us to execute the next steps in our growth strategy,” stated Clifford Reid, Ph.D., Travera’s CEO. “This CLIA certification recognizes our commitment to ensuring we meet the quality criteria to perform clinical diagnostic testing and to assist oncologists to quickly determine which drugs to prescribe based on the actual responses of their patients’ tumor cells to candidate drugs.”
Travera was founded in 2017 to commercialize a breakthrough measurement technology and biomarker developed in the Manalis Laboratory in the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT). The company’s initial test is based on this technology; a new measurement tool called the Suspended Microchannel Resonator (SMR) that makes exquisitely precise measurements of the effects of cancer drugs on cancer cells.